Compare Quantumscape Corp (QS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Quantumscape Corp trades at $3.89 (market cap $2.55B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QS | TVTX | |
|---|---|---|
Market Cap | $2.55B | $4.88B |
Volume | 12,145,789 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $67.52 |
52-Week Low | $3.93 | $26.79 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $1.76B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.12, down 3.51% with a bearish technical outlook despite oversold RSI readings. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative ROE/ROA. Recent news highlights commercialization delays and insider selling, while analyst consensus shows 73% hold ratings with a $10.35 price target representing 151% upside potential.
QS presents high-risk speculation with substantial upside if solid-state battery technology succeeds, but faces execution risks and cash burn. The stock trades near 52-week lows with negative cash flow trends, requiring careful risk management given the 5+ year commercialization timeline and competitive threats in EV battery development.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
